Literature DB >> 4029087

The electrical properties of isolated human prolactin-secreting adenoma cells and their modification by dopamine.

J M Israel, P Jaquet, J D Vincent.   

Abstract

Human prolactinoma cells were maintained in culture for a period of at least 8 days and were able to secrete PRL in large amounts. This secretion was inhibited by bromocriptine, an agonist of dopaminergic receptors, in a dose-dependent manner. The cells showed electrical activity (action potentials) which was blocked by inhibitors of calcium current (cobalt, manganese), whereas it was insensitive to blockers of sodium current (tetrodotoxin). At the resting potential of the cell, dopamine induced a hyperpolarizing response such that action potentials no longer occurred. This effect was due to increase of the membrane conductance and depended on the cell potential. The reversal potential of this response was at -100 mV, which suggests the involvement of potassium ions. Bromocriptine and RU 24213, which are strong dopaminergic receptor agonists, both induced responses identical to the dopamine-induced response. The D2 receptor antagonists (haloperidol, domperidone, and spiperone) blocked the dopamine-induced response in a reversible manner. The D1 antagonist of dopaminergic receptors flupentixol had no effect on the dopamine response. It is concluded that the dopamine modulation of electrical activity involving calcium current may be an early important step in the mechanism by which dopamine inhibits PRL release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029087     DOI: 10.1210/endo-117-4-1448

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  Endocrine cell excitability opens the way to novel pharmacological intervention: example of the anterior pituitary cell.

Authors:  J D Vincent; L A Kukstas; P M Lledo
Journal:  Cell Biol Toxicol       Date:  1992 Jul-Sep       Impact factor: 6.691

2.  TRH raises cytosolic Ca2+ in human adenomatous lactotrophs.

Authors:  A Spada; F Reza-Elahi; A Lania
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

Review 3.  Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1.

Authors:  J C Buckingham
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

4.  Restricted usefulness of tetraethylammonium and 4-aminopyridine for the characterization of receptor-operated K+-channels.

Authors:  B Drukarch; K S Kits; J E Leysen; E Schepens; J C Stoof
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

5.  Electrophysiological responses to somatostatin of rat hypophysial cells in somatotroph-enriched primary cultures.

Authors:  C Chen; J M Israel; J D Vincent
Journal:  J Physiol       Date:  1989-01       Impact factor: 5.182

Review 6.  Twelfth Gaddum memorial lecture. Drug receptors and the inhibition of nerve cells.

Authors:  R A North
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  Prosocial effects of prolactin in male rats: Social recognition, social approach and social learning.

Authors:  Mary E Donhoffner; Samar Al Saleh; Olivia Schink; Ruth I Wood
Journal:  Horm Behav       Date:  2017-09-24       Impact factor: 3.587

8.  Guanine nucleotide binding proteins mediate D2 dopamine receptor activation of a potassium channel in rat lactotrophs.

Authors:  L C Einhorn; G S Oxford
Journal:  J Physiol       Date:  1993-03       Impact factor: 5.182

9.  Electrophysiological responses to dopamine of rat hypophysial cells in lactotroph-enriched primary cultures.

Authors:  J M Israel; C Kirk; J D Vincent
Journal:  J Physiol       Date:  1987-09       Impact factor: 5.182

10.  Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas.

Authors:  A Lania; F Reza-Elahi; P Gil-del-Alamo; K Saccomanno; S Mantovani; A Spada
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.